More than 500 million people face weight challenges in China as Eli Lilly secures regulatory clearance for its oral treatment.
Pharmaphorum reported that more than half of Chinese adults are overweight or obese.
The new pill will compete directly against Lilly’s own once-weekly tirzepatide injection and Novo’s semaglutide injections. Both injectable medications have been on sale in China since 2024.
Additional competition comes from products manufactured by Pfizer and local drugmaker Innovent Biologics. Weight-loss drugs in China remain entirely self-paid without public insurance coverage. Sales come mainly from middle- and high-income city residents.
Pills Offer Alternative to Weekly Injections
- Oral Delivery vs. Injections: The newly approved pill offers an alternative to weekly subcutaneous injections like semaglutide and tirzepatide.
- Supply Chain Scaling: Eli Lilly committed $3 billion over a 10-year period to expand manufacturing capacity at plants in Suzhou and Beijing.
Lilly Invests $3 Billion in Chinese Manufacturing
Eli Lilly has not yet disclosed a Chinese price or a specific launch date for the medication. To supply the market, Lilly committed $3 billion over 10 years to its Chinese supply chain. This funding supports major expansions at manufacturing plants in Suzhou and Beijing.
Globally, Novo Nordisk still leads in oral GLP-1 medications. Pharmaphorum said that sales of Foundayo have lagged behind oral semaglutide. This dynamic persists even as Lilly takes injectable share.
A separate regulatory application for orforglipron in type 2 diabetes remains under review at the National Medical Products Administration. Meanwhile, Novo already holds Chinese approval for oral semaglutide in that specific indication.
| Company | Drug Candidate | Delivery Method | Regulatory Status in China |
|---|---|---|---|
| Eli Lilly | Orforglipron | Oral Pill | Approved for weight loss; diabetes review ongoing |
| Novo Nordisk | Semaglutide | Oral / Injection | Approved for diabetes; injections on sale since 2024 |
| Eli Lilly | Tirzepatide | Injection | On sale since 2024 |
References
- Pharmaphorum cited figures showing that more than half of Chinese adults, over 500 million people, are overweight or obese.
